Population pharmacokinetics and exposure‐response relationship for temsavir following fostemsavir administration in treatment‐experienced HIV patients

Benzer Materyaller

• SHIELD study: a multicenter, open-label, single-arm trial to evaluate the safety, pharmacokinetics and antiviral activity of fostemsavir in combination with optimized background therapy (OBT) in children and adolescents with HIV who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class antiretroviral (ARV) resistance
  Yazar:: Carlos Grasa, ve diğerleri
  Baskı/Yayın Bilgisi: (2026-02-01)
• Population pharmacokinetics and exposure‐response relationship for temsavir following fostemsavir administration in treatment‐experienced HIV patients
  Yazar:: Ridhi Parasrampuria, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-06-01)
• Mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of fostemsavir
  Yazar:: Mohsen Heidary, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-02-01)
• No dose adjustment of metformin or substrates of organic cation transporters (OCT)1 and OCT2 and multidrug and toxin extrusion protein (MATE)1/2K with fostemsavir coadministration based on modeling approaches
  Yazar:: Dung Nguyen, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-08-01)
• SUSTAINED EFFICACY, SAFETY, AND IMMUNOLOGICAL IMPROVEMENT OVER 7 YEARS WITH FOSTEMSAVIR-BASED REGIMENS IN INDIVIDUALS WITH HIV-1 AND LIMITED TREATMENT OPTIONS IN LATIN AMERICA
  Yazar:: Isabel Cristina Ferreira Tavares, ve diğerleri
  Baskı/Yayın Bilgisi: (2026-03-01)